On July 8–15, 2015, world-leading experts will be gathering in Stockholm for the 4th World Psoriasis & Psoriatic Arthritis Conference. They will discuss the current frontline in clinical research and pathophysiological understanding of all aspects related to the serious chronic diseases psoriasis and psoriatic arthritis.
Arranged by the International Federation of Psoriasis Associations (IFPA), this fourth conference of its kind recognizes the many great and recent advances that have been made within the fields of psoriasis and psoriatic arthritis.
The multidisciplinary sessions will cover subjects, such as psoriasis as a multi-organ disease. They will also give an international outlook on psoriasis and psoriatic arthritis treatment and care, and will provide delegates with the latest research and facts on biomarkers and diagnostics, genetics of psoriasis and psoriatic arthritis, long-term treatment with available therapies, and treatments in development.
Professor Dr. Peter van de Kerkhof of Radboud University Nijmegen Medical Centre, president of the 4th World Psoriasis & Psoriatic Arthritis Conference and Chairman of its Scientific Executive Committee, comments: “Our understanding of psoriasis as a complex inflammatory immune-mediated disease with significant comorbidities has made important progress over the last few years. New insights have been obtained into the pathogenesis of psoriasis and psoriatic arthritis, which are revolutionizing the treatment of the patient of today and tomorrow.
Kerkhof continues by adding, “The 4th World Psoriasis & Psoriatic Arthritis Conference will give us an excellent opportunity to discuss these significant breakthroughs with colleagues and patient leaders from all over the world. It will hopefully help improve the situation for the millions of people who suffer from these chronic diseases.”
The World Psoriasis & Psoriatic Arthritis Conferences, initiated by IFPA in 2006, are unique in that they invite dermatologists, rheumatologists, general practitioners, allied health professionals and patient leaders from all over the world to participate; creating a platform for education, networking and fostering research within psoriasis and psoriatic arthritis, with dedicated focus on the patients.
“That psoriasis is a non-communicable disease with a significant disease burden was formally recognized by a WHO resolution in May 2014,” says Lars Ettarp, President of IFPA. “It is of the highest importance for IFPA and its member organizations to ensure that the disease is understood correctly by policy makers and healthcare professionals and that the necessary steps are taken to provide people with psoriasis with the treatment and care they need and deserve.”
Ettarp adds, “The World Psoriasis & Psoriatic Arthritis Conferences are a very important part of the strategic work IFPA is doing to educate both the providers and recipients of this care and we hope to see doctors, nurses, researchers and patient leaders from all over the globe in Stockholm this summer.”
The 4th World Psoriasis & Psoriatic Arthritis Conference is for dermatologists, rheumatologists and general practitioners and allied health professionals with an interest in psoriasis and psoriatic arthritis.Visit www.ifpaworldconference.com for more information and to register.